Post-earnings recap
Reported
Thu, May 5, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Illumina's earnings report shows a solid performance on EPS, exceeding expectations by nearly 23%. However, the stock fell by over 5% in reaction, likely due to the lack of revenue figures and guidance, which leaves investors uncertain about future growth prospects. The management's comments on supply chain issues may have also contributed to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.07 | N/A | +22.85% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious optimism about demand for their products. However, they acknowledged ongoing supply chain challenges that could impact operations.
Management highlighted strong demand for genomic solutions.
They noted ongoing challenges in the supply chain affecting operations.
Future growth is expected but contingent on market conditions.